Home

Simon Read

CIK 1688199 · Chief Scientific Officer · last filed 2026-08-19

Simon Read is a Chief Scientific Officer who has filed 16 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for DNTH, was dated Aug 19, 2026. Across all open-market trades the lifetime net is −$3.1M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

16

Lifetime Open-Market Net

-$3.12M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DNTH Director 0 $106.62 $0 -$630.8K 4 2026-08-19
Ra Pharmaceuticals, Inc. (RARX) Delisted Chief Scientific Officer 0 — — -$2.49M 11 2020-04-03

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-19 DNTH Mixed — -$275.5K EDGAR
2026-08-11 DNTH Mixed — -$253.2K EDGAR
2026-08-10 DNTH Notice (144) −5,550 -$624.4K EDGAR
2026-05-22 DNTH Grant (A) — $0 EDGAR
2025-05-22 DNTH Grant (A) — $0 EDGAR
2020-04-03 Ra Pharmaceuticals, Inc. (RARX) Delisted Disp (D) −12,595 -$604.6K EDGAR
2019-12-18 Ra Pharmaceuticals, Inc. (RARX) Delisted Mixed — -$442.1K EDGAR
2019-11-18 Ra Pharmaceuticals, Inc. (RARX) Delisted Mixed — -$438.1K EDGAR
2019-10-17 Ra Pharmaceuticals, Inc. (RARX) Delisted Mixed — -$440.0K EDGAR
2019-09-16 Ra Pharmaceuticals, Inc. (RARX) Delisted Mixed — -$225.3K EDGAR
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.